The table below indicates the characteristics of patients included in the SIRFLOX study. There were no significant differences in baseline patient characteristics. A majority of patients had poor prognostic factors at baseline (extra-hepatic metastases, primary tumor in situ, synchronous metastases).
bev*: bevacizumab (bevacizumab allowed at investigator’s discretion, per institutional practice)
No statistically significant improvement of PFS at any site
van Hazel GA et al. J Clin Oncol 2016; 34: 1723–1731.